Show newer
arawat

Neoantigen based Personalized Cancer Therapeutic Vaccines Market

Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body’s immune system to fight cancer.
Neoantigens are non-autologous proteins which are specific to individuals and are a result of non-synonymous mutations in the tumor cell genome.

Bioinformatics-technological advancements, improved diagnosis, and a strong pipeline are some of the factors contributing to the advancement of Neoantigen based Personalized Cancer Therapeutic Vaccines Market.
Several key players such as Gradalis, OSE Immunotherapeutics, Immunitor, Gritstone Oncology, Genocea, Targovax, Hangzhou Neoantigen Therapeutics, Neon Therapeutics along with many others are robustly involved in fuelling Neoantigen-based Personalized Cancer therapeutic Vaccines market.

For more details visit: delveinsight.com/blog/neoantig

0
arawat

COVID-19 Diagnostic Projects

The rapid spread of Coronavirus has put the healthcare agencies in a perilous position as they are running out of the diagnostics kits.

To deal with the current situation, governments and companies around the world are working in collaboration to fulfil the current COVID-19 diagnostics demand.
Globally a large number of diagnostic projects are going on to boost testing for covid19.

Some of the projects such as Northwestern University’s One step diagnostic tool, LabCorp’s at home COVID19 test kit, Innovative Genomics Institute's automated COVID-19 Diagnostic Testing and many others are likely to make a significant contribution to COVID-19 detection in coming weeks.

For more details visit:
delveinsight.com/blog/covid-19

0
arawat

Copper Kills Coronavirus

The viruses and other micro-organisms have a longer life-span on some surfaces compared with others. Similarly, novel coronavirus -SARS-CoV-2 lives longer on some surfaces than others.

According to a paper published in The New England Journal of Medicine (NEJM), which evaluated the stability of SARS-CoV-2 in aerosols and other surfaces, estimated that SARS-CoV-2 was able to persist more on plastic and stainless steel than on copper and cardboard.

Scientists are now examining the antimicrobial property of copper for preventing and controlling the transmission of SARS-CoV-2.

For more details visit:
delveinsight.com/blog/novel-co

0
arawat

Hydroxychloroquine, COVID-19, and Clinical trials

Hydroxychloroquine (aka hydroxychloroquine sulfate), is a drug available in the market to treat a range of disorders including Malaria, and Autoimmune disorders such as lupus and Rheumatoid arthritis.

US FDA has given the Emergency Use Authorization to the drug for its use in adolescent and adult patients with COVID-19. But the doctors and physicians are sceptical in prescribing the medication outlining potential health risks, including Heart Rhythms.
Dozens of clinical studies are ongoing to study the efficacy and safety of the drug Hydroxychloroquine in fighting covid19.

For more details visit: delveinsight.com/blog/hydroxyc

0
arawat

Demand for ventilators amid the Coronavirus crisis

A surge in demand for the ventilators has been observed throughout the countries going through the COVID19 crisis.
The sudden increments in the transmission of COVID-19 over a short period of time have disrupted the global demand-supply chain of ventilators.

Ventilator manufacturing companies have scaled up their existing production capacity & some of the biggest ventilator manufacturers like Getinge, Hamilton Medical, Dräger, BD, Philips, Medtronics Ltda, are working round the clock to fulfil the current demand of ventilators.

For more information visit: delveinsight.com/blog/why-vent

0
arawat

CAR-T cell therapy market for Non-Hodgkin lymphoma

As per DelveInsight, the CART Cell Therapy Market size for Non-Hodgkin Lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.

Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.
Several companies, including Celgene, and Gilead Sciences, are working to fuel the CAR-T cell therapy market for Non-Hodgkin lymphoma. The expected launch of Lisocabtagene maraleucel (also known as JCAR017) of Celgene’s, (a Bristol Myers Squibb company) and KTE-X19 by Gilead Sciences will significantly drive the NHL market in the near future.

For more details visit: delveinsight.com/blog/car-t-ce

0
arawat

Guillain–Barré Syndrome
Market Analysis, Epidemiology and Market Forecast to 2030

Guillain–Barré Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with a brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently.
Most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.

DelveInsight's "Guillain–Barré Syndrome Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Guillain–Barré Syndrome , historical and forecasted epidemiology as well as the Guillain–Barré Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Guillain–Barré Syndrome market report provides current treatment practices, emerging drugs, Guillain–Barré Syndrome market share of the individual therapies, current and forecasted Guillain–Barré Syndrome market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Guillain–Barré Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit: delveinsight.com/report-store/

0
arawat

Chronic Inflammatory Demyelinating Polyneuropathy
Market Analysis, Epidemiology and Market Forecast to 2030

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibres) of the peripheral nerves.

Although CIDP can occur at any age and in both genders, it is more common in men than women and the highest number of people affected with CIDP are found in the age-group of 65 and above years.

Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis
The Chronic Inflammatory Demyelinating Polyneuropathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Inflammatory Demyelinating Polyneuropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The market segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
For more details visit:
delveinsight.com/report-store/

0
arawat

Tuberous Sclerosis Complex Market
Analysis, Epidemiology and Market Forecast to 2030

Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by the growth of numerous non-cancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. It was firstly described in the 1880s by French neurologist Désiré-Magloire Bourneville.

TSC is a neurocutaneous disorder that is caused by mutations in one of the two different genes called TSC1 and TSC2. These two genes lead to a protein product, called hamartin and tuberin. Both of these are involved in a complicated schema of normal cell signalling pathways. Any mutation in either of the TSC gene disrupts the main pathways, resulting in further alteration in cellular differentiation, growth, and proliferation. TSC alters the cellular proliferation and differentiation, resulting in hamartomas of various organs, tumour formation, and altered neuronal migration.

DelveInsight's "Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Tuberous Sclerosis Complex , historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Tuberous Sclerosis Complex market report provides current treatment practices, emerging drugs, Tuberous Sclerosis Complex market share of the individual therapies, current and forecasted Tuberous Sclerosis Complex market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Tuberous Sclerosis Complex treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit:
delveinsight.com/report-store/

0
arawat

Genital Herpes Market Analysis, Epidemiology and
Market Forecast 2030

Genital Herpes (GH), is a common sexually transmitted disease caused due to two viruses namely: herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) characterized by lifelong infection and periodic reactivation with no cure. Viruses penetrate the body through mucous membranes which line the openings of nose, mouth and genitalia.HSV1, HSV2 are found in body fluids of infected person.

The appearance of a blister is known as outbreak. First outbreak will appear as early as two days after the virus has been contracted, or as late as 30 days afterward. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving

Genital Herpes Market
The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

For more details visit:
delveinsight.com/report-store/

0
arawat

Artificial Intelligence and Novel Coronavirus (COVID-19) crisis
The novel coronavirus within a span of five-month has infected around 1 million people, resulting in deaths of 50,000 people in over 180 countries around the world till date.
To deal with the spread and diagnosis of coronavirus, tech-companies and governments around the are working in collaboration to use AI-based solutions to contain and mitigate its further transmission.
Some of the artificial intelligence-based solutions such as Interactive voice response systems & chatbots, thermal and face recognition cameras, disease transmission detector etc is playing key role in the Mitigation and Control of Coronavirus.

For more details visit: delveinsight.com/blog/artifici

0
arawat

CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL)
Acute lymphocytic leukemia (ALL) is a tumor that afflicts bone marrow and hampers the production of healthy White blood cells. ALL is acute cancer denoting its rapid progression, if not treated can be fatal within a few months.
DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry.
The Acute Lymphoblastic Leukemia market consists of the big pharma players as well as the mid-sized companies, hence is moderately competitive. Some of the leading companies in Acute Lymphoblastic Leukemia market includes Miltenyi Biotec, Precision BioSciences, Autolus Limited. MB-CART19.1, PBCAR0191, AUTO3 are some of the emerging therapies in Acute Lymphoblastic Leukemia market.

For more details visit: delveinsight.com/blog/car-t-ce

0
arawat

Warm Autoimmune Hemolytic Anemia Market Forecast and Pipeline Analysis
In 2017, as per the estimates by DelveInsight, Warm Autoimmune Haemolytic Anemia had affected 82,045 people approximately in the 7MM. WAIHA affects around 1 in 35,000 people in North America. With a population of about 57 crores, WAIHA is a cause of distress to many living in that continent only, let alone worldwide.
As of now, there exists no FDA-approved therapy in the Warm autoimmune hemolytic anemia market for patients to rely on.
The current Warm Autoimmune Haemolytic Anemia market is positively evolving and will continue to grow at a CAGR of 15.9% in the 7MM by 2030 estimates DelveInsight Warm autoimmune hemolytic anemia forecast analysis for the period 2019-2030.
Improvement in the diagnosis methodologies and incremental healthcare spending across the world are going to add to the Warm Autoimmune Hemolytic Anemia market leading towards the development of new treatment therapies, addressed challenges, and a better approach towards treating Warm autoimmune hemolytic anemia treatment.

delveinsight.com/blog/warm-aut

0
arawat

Warm Autoimmune Hemolytic Anemia Epidemiology Analysis
As per DelveInsight’s Warm Autoimmune hemolytic Anemia epidemiology forecast and analysis, Warm Autoimmune hemolytic Anemia prevalence in the 7MM was estimated to be around 82,045 cases.

Despite being a prevalence of 82,045 in the 7MM in 2017, there is no validated and standard FDA-approved therapeutic option available in the wAIHA therapy market.
It poses a considerable burden on the global healthcare system, with most Warm Autoimmune hemolytic Anemia patients not been able to achieve a standard cure.
However, to redress the current unmet needs in the Warm Autoimmune hemolytic Anemia therapy market, many pharma and biotech companies are working to advance the wAIHA market with several products in the pipeline which is expected to positively shirt the Warm Autoimmune hemolytic Anemia therapy market in upcoming years.

For more details visit: delveinsight.com/blog/warm-aut

0
arawat

What is driving Retinitis pigmentosa market forward?

Retinitis Pigmentosa is a heterogeneous, progressive disease, leading to worsening of the vision over time.
Treatment of Retinitis Pigmentosa is as big of a challenge as its diagnosis is.
Management, prognosis, diagnosis of the disease has always been an uphill task. Incomplete understanding, heterogeneity, complex pathophysiology and involvement of numerous genes are the major hurdles needed to be overcome in the Retinitis pigmentosa market

Several pharma and biotech companies including HORA-RPE65 ( Horama), AAV8-RPGR (NIGHTSTAR THERAPEUTICS), jCell (jCyte, Inc.), Renexus (NT-501; Neurotech Pharmaceuticals, Inc.), and hRPC (RENEURON LIMITED) are expected to enter into Retinitis pigmentosa market in the coming decade.

For more details visit: delveinsight.com/blog/retiniti

0
arawat

Realm of Pandemics

COVID19, a novel coronavirus after toppling down China, has managed to create havoc in the entire world, with people fearing the impending doom.
However, the recent outbreak of coronavirus is not the first time that the human race is hit by a pandemic. Throughout the journey of human existence plagues, viral infections and other Pandemic diseases have caused severe and extensive damage to its existence. Typhoid, influenza, smallpox, and measles are some of the examples of worst pandemics that wreaked havoc on civilizations of that time.

For a more detailed understanding of Pandemic diseases, their classification and the impact that they have caused on human civilization visit: delveinsight.com/blog/realm-of

0
arawat

Telemedicine: Future of Healthcare

Telemedicine is one of the fastest-growing domains in the healthcare industry. Telemedicine is the practice of providing healthcare services like evaluation, diagnosis and treatment to the patients using telecommunication technology where both the healthcare provider and patient are present at different locations.
Telemedicine today is in use for treatment and diagnosis of a wide variety of acute and chronic infectious diseases. Some of the common conditions include sore throat, Diarrhea, Colds and Flu, Arthritic Pain, Allergies, Sprains & Strains, Bladder Infections, congestive heart failure, diabetes, obstructive pulmonary disease, Skin Inflammations, Sinusitis, Conjunctivitis, Pharyngitis, Respiratory Infections, Rashes and many more.
The Telemedicine services include three primary functions- Interactive Media, Store and Forward, and Remote Patient Monitoring System.
The higher demand from working professionals, easy to use services (user-friendly applications & software system), time-saving, cost-effective services, healthcare broker (health insurance) and technological progress in healthcare are some of the factors which are expected to drive the Telemedicine market in upcoming years.
For more detailed information visit: delveinsight.com/blog/telemedi

0
arawat

Optic Neuritis Market Analysis, Epidemiology and Market Forecast 2030

DelveInsight's "Optic Neuritis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Optic Neuritis market report provides current treatment practices, emerging drugs, Optic Neuritis market share of the individual therapies, current and forecasted Optic Neuritis market Size from 2017 to 2030 segmented by seven major markets.

The Report also covers current Optic Neuritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit: delveinsight.com/report-store/

0
arawat

Helicobacter Pylori (H. pylori) infection Market Size, Trend, and Growth

DelveInsight's "Helicobacter Pylori (H. pylori) Infection - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Helicobacter Pylori (H. pylori) Infection, historical and forecasted epidemiology as well as the Helicobacter Pylori (H. pylori) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Helicobacter Pylori (H. pylori) Infection market report provides current treatment practices, emerging drugs, Helicobacter Pylori (H. pylori) Infection market share of the individual therapies, current and forecasted Helicobacter Pylori (H. pylori) Infection market Size from 2017 to 2030 segmented by seven major markets.

The Report also covers current Helicobacter Pylori (H. pylori) Infection treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit: delveinsight.com/report-store/

0
arawat

Haemophilia A Market Analysis, Epidemiology and Market Forecast 2030

DelveInsight's "Hemophilia A - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hemophilia A market report provides current treatment practices, emerging drugs, Hemophilia A market share of the individual therapies, current and forecasted Hemophilia A market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Hemophilia A treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

For more details visit: delveinsight.com/report-store/

0
Show older
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.

Trending now

Resources

Developers

What is Mastodon?

qoto.org

More…

v3.5.19-qoto · Privacy policy